Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Cash from Investing Activities: 2017-2025

Historic Cash from Investing Activities for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to $13.8 million.

  • Aclaris Therapeutics' Cash from Investing Activities rose 394.81% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$50.7 million, marking a year-over-year decrease of 291.39%. This contributed to the annual value of -$69.8 million for FY2024, which is 250.95% down from last year.
  • Aclaris Therapeutics' Cash from Investing Activities amounted to $13.8 million in Q3 2025, which was up 174.02% from $5.0 million recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Cash from Investing Activities registered a high of $32.5 million during Q3 2023, and its lowest value of -$88.7 million during Q4 2024.
  • In the last 3 years, Aclaris Therapeutics' Cash from Investing Activities had a median value of $7.5 million in 2023 and averaged $1.3 million.
  • Per our database at Business Quant, Aclaris Therapeutics' Cash from Investing Activities soared by 2,573.29% in 2023 and then crashed by 1,275.14% in 2024.
  • Aclaris Therapeutics' Cash from Investing Activities (Quarterly) stood at -$9.2 million in 2021, then surged by 129.45% to $2.7 million in 2022, then soared by 179.42% to $7.5 million in 2023, then crashed by 1,275.14% to -$88.7 million in 2024, then skyrocketed by 394.81% to $13.8 million in 2025.
  • Its Cash from Investing Activities stands at $13.8 million for Q3 2025, versus $5.0 million for Q2 2025 and $19.1 million for Q1 2025.